Approval times can vary
Unlike Ozempic and Wegovy, which primarily focus on GLP-1, Mounjaros unique approach improves insulin secretion while reducing glucagon production
In the pivotal clinical trials that supported FDA approval, adults taking oral semaglutide achieved significantly greater weight loss compared with placebo, averaging around 13.6% weight reduction over 64 weeks in one study
Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes
[7] [8] Remember that Wegovy is intended for long-term use as part of a comprehensive lifestyle intervention
Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, et al